Literature DB >> 33988976

Pulsed Hydrogen-Deuterium Exchange Reveals Altered Structures and Mechanisms in the Aggregation of Familial Alzheimer's Disease Mutants.

Eva Illes-Toth1, Georg Meisl2, Don L Rempel1, Tuomas P J Knowles2, Michael L Gross1.   

Abstract

Mutations of the Amyloid Precursor Protein, from which the amyloid β peptide Aβ42 is cleaved, are associated with familial Alzheimer's disease. The disease-relevant familial mutations include the Arctic (E22G), Iowa (D23N), Italian (E22K), Dutch (E22Q), Japanese (D7N), English (D6R), and Flemish (A21G) variants. A detailed mechanistic understanding of the aggregation behavior of the mutant peptides at the residue level is, however, still lacking. We report here a study of the aggregation kinetics of these mutants in vitro by pulsed hydrogen-deuterium exchange mass spectrometry (HDX-MS) to obtain a temporally and sequence resolved picture of their self-assembly. For all variants, HDX occurs to give a bimodal distribution representing two soluble classes of aggregates, one protected and one solvent-exposed. There is no evidence of other classes of structural intermediates within the detection limits of the HDX approach. The fractional changes in the bimodal exchange profiles for several regions of Aβ42 reveal that the central and C-terminal peptides gain protection upon fibril formation, whereas the N-terminal regions remain largely solvent-accessible. For these mutants, all peptide fragments follow the same kinetics, acquiring solvent protection at the same time, further supporting that there are no significant populations of intermediate species under our experimental conditions. The results demonstrate the potential of pulsed HDX-MS for resolving the region-specific aggregation behavior of Aβ42 isoforms in solution where X-ray crystallography and solid-state NMR (ssNMR) are challenged.

Entities:  

Keywords:  Aβ42 peptide; aggregation; amyloid structure; disease-associated mutants; kinetics; pulsed hydrogen−deuterium exchange

Mesh:

Substances:

Year:  2021        PMID: 33988976      PMCID: PMC8894311          DOI: 10.1021/acschemneuro.1c00072

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   5.780


  67 in total

1.  Atomic Resolution Structure of Monomorphic Aβ42 Amyloid Fibrils.

Authors:  Michael T Colvin; Robert Silvers; Qing Zhe Ni; Thach V Can; Ivan Sergeyev; Melanie Rosay; Kevin J Donovan; Brian Michael; Joseph Wall; Sara Linse; Robert G Griffin
Journal:  J Am Chem Soc       Date:  2016-07-14       Impact factor: 15.419

2.  Pulsed hydrogen-deuterium exchange mass spectrometry probes conformational changes in amyloid beta (Aβ) peptide aggregation.

Authors:  Ying Zhang; Don L Rempel; Jun Zhang; Anuj K Sharma; Liviu M Mirica; Michael L Gross
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-19       Impact factor: 11.205

3.  A Multifunctional Chemical Agent as an Attenuator of Amyloid Burden and Neuroinflammation in Alzheimer's Disease.

Authors:  Hong-Jun Cho; Anuj K Sharma; Ying Zhang; Michael L Gross; Liviu M Mirica
Journal:  ACS Chem Neurosci       Date:  2020-05-04       Impact factor: 4.418

4.  Hereditary cerebral hemorrhage with amyloidosis associated with the E693K mutation of APP.

Authors:  Orso Bugiani; Giorgio Giaccone; Giacomina Rossi; Michela Mangieri; Raffaella Capobianco; Michela Morbin; Giulia Mazzoleni; Chiara Cupidi; Gabriella Marcon; Annarita Giovagnoli; Alberto Bizzi; Giuseppe Di Fede; Gianfranco Puoti; Francesco Carella; Andrea Salmaggi; Alessandro Romorini; Giorgio M Patruno; Mauro Magoni; Alessandro Padovani; Fabrizio Tagliavini
Journal:  Arch Neurol       Date:  2010-08

5.  Differences in nucleation behavior underlie the contrasting aggregation kinetics of the Aβ40 and Aβ42 peptides.

Authors:  Georg Meisl; Xiaoting Yang; Erik Hellstrand; Birgitta Frohm; Julius B Kirkegaard; Samuel I A Cohen; Christopher M Dobson; Sara Linse; Tuomas P J Knowles
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-17       Impact factor: 11.205

6.  Synthesis, aggregation, neurotoxicity, and secondary structure of various A beta 1-42 mutants of familial Alzheimer's disease at positions 21-23.

Authors:  Kazuma Murakami; Kazuhiro Irie; Akira Morimoto; Hajime Ohigashi; Mayumi Shindo; Masaya Nagao; Takahiko Shimizu; Takuji Shirasawa
Journal:  Biochem Biophys Res Commun       Date:  2002-05-31       Impact factor: 3.575

7.  Effect of the English familial disease mutation (H6R) on the monomers and dimers of Aβ40 and Aβ42.

Authors:  Man Hoang Viet; Phuong H Nguyen; Philippe Derreumaux; Mai Suan Li
Journal:  ACS Chem Neurosci       Date:  2014-06-30       Impact factor: 4.418

8.  Amyloid precursor protein mutation E682K at the alternative β-secretase cleavage β'-site increases Aβ generation.

Authors:  Lujia Zhou; Nathalie Brouwers; Iryna Benilova; Annelies Vandersteen; Marc Mercken; Koen Van Laere; Philip Van Damme; David Demedts; Fred Van Leuven; Kristel Sleegers; Kerensa Broersen; Christine Van Broeckhoven; Rik Vandenberghe; Bart De Strooper
Journal:  EMBO Mol Med       Date:  2011-04-15       Impact factor: 12.137

Review 9.  An Inflammation-Centric View of Neurological Disease: Beyond the Neuron.

Authors:  Stephen D Skaper; Laura Facci; Morena Zusso; Pietro Giusti
Journal:  Front Cell Neurosci       Date:  2018-03-21       Impact factor: 5.505

10.  Modulation of electrostatic interactions to reveal a reaction network unifying the aggregation behaviour of the Aβ42 peptide and its variants.

Authors:  Georg Meisl; Xiaoting Yang; Christopher M Dobson; Sara Linse; Tuomas P J Knowles
Journal:  Chem Sci       Date:  2017-04-26       Impact factor: 9.825

View more
  2 in total

Review 1.  Neglected N-Truncated Amyloid-β Peptide and Its Mixed Cu-Zn Complexes.

Authors:  Tomasz Frączyk; Piotr Cieplak
Journal:  Protein J       Date:  2022-06-01       Impact factor: 4.000

Review 2.  Characterizing Endogenous Protein Complexes with Biological Mass Spectrometry.

Authors:  Rivkah Rogawski; Michal Sharon
Journal:  Chem Rev       Date:  2021-08-18       Impact factor: 72.087

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.